Entasis is a biopharmaceutical company dedicated to developing innovative antibacterial products that treat severe infections caused by multiplex-resistant Gram-negative bacteria. Their platform focuses on targeting specific pathogens, yielding a strong pipeline of product candidates such as sulbactam-durlobactam for Acinetobacter baumannii infection, zoliflodacin for Neisseria gonorrhoeae infection, ETX0282CPDP for Enterobacteriaceae infection, and ETX0462 for Pseudomonas infection. The company is currently in a clinical stage, with a mission to commercialize potentially life-saving treatments.